Takeda’s Mezagitamab Delivers Sustained Platelet Boost In Phase 2 Clinical Trials For Treatment of Immune Thrombocytopenia Purpura
Mezagitamab achieved a sustained platelet response and symptomatic relief in patients treated for chronic ITP. Mezagitamab showed a favorable safety ...
